TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28948366
Drug: G/P (glecaprevir/pibrentasvir)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G/P (glecaprevir/pibrentasvir) 300/120 mg once daily for 8 weeks
Study: 28948366
Drug: OBV/PTV/r (ombitasvir/paritaprevir/ritonavir)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBV/PTV/r (ombitasvir/paritaprevir/ritonavir) 25/150/100 mg for 12 weeks
Study: 28948366
Drug: G/P (glecaprevir/pibrentasvir)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G/P (glecaprevir/pibrentasvir) 300/120 mg once daily for 12 weeks
Study: 23403419
Drug: Tigecycline 50
Normalized name: tigecycline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigecycline 50 mg
Study: 23403419
Drug: Tigecycline 200
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tigecycline 200 mg
Study: 16750022
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg x m(‐2) YH‐16
Study: 16750022
Drug: 15 mg/m(2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/m(2) YH‐16
Study: 14500805
Drug: Parathyroid hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parathyroid hormone (40 microg subcutaneously daily)
Study: 10768519
Drug: Amoxycillin/clavulanate 45/6.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanate 45/6.4 mg/kg/day twice-daily (b.d.)
Study: 10768519
Drug: Amoxycillin/clavulanate 40/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanate 40/10 mg/kg/day three-times-daily (t.d.s.)
Study: 10768519
Drug: Amoxycillin/clavulanate twice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanate twice-daily (b.d.)
Study: 10768519
Drug: Amoxycillin/clavulanate three-times-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanate three-times-daily (t.d.s.)
Study: 8620818
Drug: Long-term oral
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oral acyclovir (600-800 mg/day)
Study: 8620818
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic therapy (group B)
Study: 2666140
Drug: Cromakalim 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromakalim 1 mg as a single daily oral dose for 5 days
Study: 28032271
Drug: CBT-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-based treatment for Specific Phobias
Study: 18292453
Drug: Prehydration with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehydration with 10 mL/kg of lactated Ringer's solution
Study: 8931648
Drug: Recombinant growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant growth hormone 0.05 IU/kg/d
Study: 15902121
Drug: 200-microg buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-microg buccal misoprostol
Study: 10489664
Drug: Tropisetron administration
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron administration before and 4 days after cisplatin treatment
Study: 10489664
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration after tropisetron before cisplatin treatment
Study: 9772614
Drug: Fumigation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fumigation and inhalation of Huayin Powder
Study: 1833088
Drug: GR32191B (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR32191B (80 mg orally before angioplasty and 80 mg/day orally for 6 months)
Study: 1833088
Drug: Control (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (250 mg i.v. aspirin before angioplasty and placebo for 6 months)
Study: 30147355
Drug: Oral methylnaltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methylnaltrexone 150 mg/day
Study: 30147355
Drug: Oral methylnaltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methylnaltrexone (combined groups)
Study: 22196510
Drug: Moxibustion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion therapy to CV4 and CV8 for 4 weeks (administered three times per week)
Study: 18804894
Drug: Concomitant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemoradiotherapy (CT-RT) with cisplatin (CDDP) 60 mg/m², gemcitabine (GEM) 1g/m² on days 1 and 8, and vinorelbine (VNR) 25 mg/m² on days 1 and 8, followed by reduced dosage during radiotherapy (66Gy) in arm A.
Study: 18804894
Drug: Concomitant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemoradiotherapy (CT-RT) with cisplatin (CDDP) 60 mg/m², gemcitabine (GEM) 1g/m² on days 1 and 8, and vinorelbine (VNR) 25 mg/m² on days 1 and 8, followed by reduced dosage during radiotherapy (66Gy) in arm B.
Study: 29056859
Drug: Buprenorphine transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine transdermal system (BTDS) 5 μg/h titrated to 20 μg/h, once weekly for 6 weeks
Study: 29056859
Drug: Oral tramadol/acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tramadol/acetaminophen (TA) 37.5 mg/325 mg, titrated to 4 tablets, twice daily for 6 weeks
Study: 24023492
Drug: 4‐L PEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐L PEG
Study: 21129718
Drug: High-dose treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose treatment (atorvastatin 80 mg/day)
Study: 21129718
Drug: Moderate-dose treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose treatment (atorvastatin 10 mg/day in TNT and simvastatin 20 to 40 mg/day in IDEAL)
Study: 19920722
Drug: LidoDin cream
Normalized name: lidocaine hydrochloride Mucosal Spray [Lidodan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LidoDin cream
Study: 11090260
Drug: Encapsulated algae-derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated algae-derived DHA oil (0.57 g DHA/day) and fungal-derived AA oil (0.26 g AA/day) for 4 weeks
Study: 8457236
Drug: Dried garlic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried garlic powder (Sapec) 900 mg
Study: 30893271
Drug: CD101 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD101 3% gel applied intravaginally on days 1 and 2
Study: 30893271
Drug: CD101 6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD101 6% ointment applied intravaginally on day 1
Study: 30893271
Drug: Oral fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fluconazole 150 mg on day 1
Study: 25118610
Drug: Magnesium carbonate
Normalized name: Magnesium Carbonate
DrugBank: Magnesium carbonate (DB09481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium carbonate plus calcium acetate as a phosphate binder (Mg group)
Study: 25118610
Drug: Magnesium carbonate
Normalized name: Magnesium Carbonate
DrugBank: Magnesium carbonate (DB09481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium carbonate plus calcium acetate (Mg group)
Study: 11999549
Drug: Soy isoflavone
Normalized name: soy isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavone extract (61.8 mg of isoflavones)
Study: 30576030
Drug: Loss of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loss of diagnosis (both treatments)
Study: 25623883
Drug: Bitter melon
Normalized name: BITTER MELON
DrugBank: Momordica charantia fruit (DB14265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitter melon 2 g/day
Study: 25623883
Drug: Bitter melon
Normalized name: BITTER MELON
DrugBank: Momordica charantia fruit (DB14265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitter melon 4 g/day
Study: 17710804
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) treatment, applied once daily for 30 minutes, with 2-3 courses on average
Study: 17710804
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment for liver protection
Study: 6379505
Drug: Propranolol 160
Normalized name: propranolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 160 mg/d
Study: 11972164
Drug: Formoterol 12
Normalized name: formoterol 12 mcg inhalation capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 12 mg
Study: 11972164
Drug: Formoterol 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 24 mg
Study: 11972164
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 mg
Study: 11972164
Drug: Salmeterol 100
Normalized name: fluticasone-salmeterol 100 mcg-50 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 100 mg
Study: 8602658
Drug: Alfentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil at target concentrations of 0 ng/ml (Group A)
Study: 8602658
Drug: Alfentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil at target concentrations of 50 ng/ml (Group B)
Study: 8602658
Drug: Alfentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil at target concentrations of 200 ng/ml (Group C)
Study: 8602658
Drug: Alfentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil at target concentrations of 400 ng/ml (Group D)
Study: 8602658
Drug: Alfentanil (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (0 to 500 ng/ml)
Study: 1418778
Drug: Zidovudine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (250 mg every 6 h)
Study: 1777174
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of zidovudine and acyclovir (800 mg every 6 h)
Study: 27792047
Drug: Ropivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine plus dexmedetomidine (20 ml ropivacaine 0.5% plus 1 ml dexmedetomidine 100 µg/ml)
Study: 27792047
Drug: Ropivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine plus placebo (20 ml ropivacaine 0.5% plus 1 ml saline)
Study: 23413781
Drug: Amlodipine/valsartan (5/160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/valsartan (5/160 mg once a day for 3 days) plus hydration (1 mL/kg/h sodium chloride infusion for 24 hours)
Study: 23413781
Drug: Hydration only
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration only (1 mL/kg/h sodium chloride infusion for 24 hours)
Study: 9620911
Drug: Inhaled recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled recombinant human IL-4
Study: 9620911
Drug: Placebo (vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle inhalation)
Study: 2668247
Drug: Netilmicin 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netilmicin 4.5 mg/kg once daily (od)
Study: 2668247
Drug: Netilmicin 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netilmicin 1.5 mg/kg thrice daily (tid)
Study: 29415833
Drug: l-arginine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine (6 g/day for 7 days)
Study: 24839047
Drug: Sublingual fentanyl
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual fentanyl orally disintegrating tablet
Study: 23816726
Drug: Eradication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication treatment for Helicobacter pylori infection
Study: 11333069
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT) with varying electrode placement and stimulus intensity; lorazepam PRN (3 mg/day) was allowed.
Study: 11333069
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT) with unilateral or bilateral application.
Study: 11333069
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT) for bipolar patients (BP I and BP II).
Study: 8507109
Drug: Regular oral
Normalized name: infant formula,regular ORAL PACKET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular oral diet (Control)
Study: 2435356
Drug: Phenoxybenzamine 10
Normalized name: phenoxybenzamine 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenoxybenzamine 10 mg/day for 5 weeks
Study: 24698126
Drug: Local heat
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local heat therapy (hot pack warmed to 50 °C)
Study: 24698126
Drug: Placebo heat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo heat therapy (hot pack warmed to 37 °C)
Study: 21234866
Drug: BCG plus
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG plus prulifloxacin (600 mg single oral dose 6 hours after instillation)
Study: 12819631
Drug: Herbal ointment
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal ointment applied to affected joint(s) for 42 days
Study: 12819631
Drug: Sham ointment
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ointment applied to affected joint(s) for 42 days
Study: 12819631
Drug: Herbal ointment
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal ointment
Study: 8061263
Drug: pipecuronium (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: pipecuronium (0.15 mg/kg)
Study: 8061263
Drug: doxacurium (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxacurium (0.08 mg/kg)
Study: 2456424
Drug: Operation plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operation plus preoperative and postoperative therapy with cisplatin, vindesine, and bleomycin (n = 19)
Study: 2456424
Drug: Patients responding
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients responding to chemotherapy preoperatively
Study: 2456424
Drug: Nonresponders to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonresponders to chemotherapy
Study: 30829209
Drug: Candicure (polyherbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candicure (polyherbal formulation)
Study: 30829209
Drug: Fluconazole therapy
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole therapy (control drug)
Study: 25966264
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba tablets (GBT) 19.2 mg three times a day for 3 months along with conventional anti-platelet aggregation treatment
Study: 25966264
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with 75 mg aspirin three times a day for 3 months
Study: 25966264
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba tablets (GBT)
Study: 22398345
Drug: Iyengar yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iyengar yoga program (twice-weekly classes for 8 weeks)
Study: 22398345
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual daily routines)
Study: 8739145
Drug: Palatal plate
Normalized name: malate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palatal plate therapy
Study: 11370751
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no palatal plate therapy)
Study: 9212478
Drug: Oral controlled-release
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral controlled-release morphine (MST)
Study: 3663878
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of adinazolam (40 mg)
Study: 3663878
Drug: Steady-state dosing
Normalized name: CLOZAPINE (GOLDEN STATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steady-state dosing of adinazolam (final dose rates of 1, 2, and 3 mg h‐1)
Study: 29364091
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of Lamivudine (LAM) and Adefovir Dipivoxil (ADV)
Study: 29364091
Drug: 12-week optimized
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week optimized therapy of Adefovir Dipivoxil (ADV) after Lamivudine (LAM)
Study: 29364091
Drug: 24-week optimized
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-week optimized therapy of Adefovir Dipivoxil (ADV) after Lamivudine (LAM)
Study: 29364091
Drug: Combination therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy, 12-week optimized therapy, and ETV monotherapy
Study: 25530151
Drug: Cocoa flavanols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa flavanols (CF) 1.4-10.9 mg/kg bw
Study: 25530151
Drug: Inorganic nitrate
Normalized name: Organic germanium
DrugBank: Propagermanium (DB17608)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inorganic nitrate 0.1-10 mg/kg bw
Study: 25530151
Drug: Nitrate (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate (3 or 8.5 mg/kg bw) followed by CF (2.7 or 10.9 mg/kg bw)
Study: 21610559
Drug: High-volume wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume wound infiltration with ropivacaine 0.2% with epinephrine (10 μg/mL)
Study: 16972834
Drug: Tramadol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (2 mg.kg‐1 tramadol in 0.2 ml.kg‐1 saline)
Study: 16972834
Drug: Bupivacaine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (0.2 ml.kg‐1 0.25% bupivacaine)
Study: 16972834
Drug: Intramuscular tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular tramadol (2 mg.kg‐1 tramadol injected 20 minutes before end of surgery)
Study: 10908213
Drug: Bosentan (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (50, 150, and 300 mg administered at 2-hour intervals)
Study: 9156659
Drug: GM-CSF (molgramostim)
Normalized name: axatilimab-csfr
DrugBank: Regramostim (DB05386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF (molgramostim) 8 mg/kg/d for 14 days
Study: 7798818
Drug: Morphine slow
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine slow release tablet (MST)
Study: 7798818
Drug: Morphine sulphate
Normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulphate solution (MSS)
Study: 24678979
Drug: Evolocumab (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (420 mg) every 4 weeks
Study: 24678979
Drug: Evolocumab (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (420 mg) with background therapy of diet alone
Study: 24678979
Drug: Evolocumab (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (420 mg) with background therapy of atorvastatin 10 mg
Study: 24678979
Drug: Evolocumab (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (420 mg) with background therapy of atorvastatin 80 mg
Study: 24678979
Drug: Evolocumab (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (420 mg) with background therapy of atorvastatin 80 mg plus ezetimibe 10 mg
Study: 8147547
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine (3 micrograms/kg per minute)
Study: 16575844
Drug: Integrated Treatment
Normalized name: Bag Spike + Integrated Clave
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Treatment (IT)
Study: 24597469
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (Control Group)
Study: 20565953
Drug: Drugs in
Normalized name: Other antiobesity drugs in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs in reverse order (Arm B)
Study: 17407241
Drug: TNF-blocking drug
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF-blocking drug
Study: 10695094
Drug: amoxycillin/clavulanate 875/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxycillin/clavulanate 875/125 mg twice daily
Study: 10695094
Drug: amoxycillin/clavulanate 500/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxycillin/clavulanate 500/125 mg three times daily
Study: 8620702
Drug: BAY u3405
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY u3405 (75 mg orally, twice a day for 2 weeks)
Study: 8620702
Drug: Placebo (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral, twice a day for 2 weeks)
Study: 6285241
Drug: Ifosfamide monotherapy
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide monotherapy
Study: 6285241
Drug: Symptomatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic therapy (control group)
Study: 27830365
Drug: Haloperidol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (5 mg) administered daily during postoperative days 0-5
Study: 22000309
Drug: Valproate (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valproate (20 mg/kg)
Study: 22000309
Drug: Valproate (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valproate (20 mg/kg) with diazepam
Study: 22000309
Drug: Phenytoin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (20 mg/kg) with diazepam
Study: 19016706
Drug: Tacalcitol ointment
Normalized name: tacalcitol
DrugBank: Tacalcitol (DB13689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacalcitol ointment plus sunlight exposure
Study: 19016706
Drug: Vehicle (placebo)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (placebo) ointment plus sunlight exposure
Study: 11422014
Drug: Sinistrin (2500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinistrin (2500 mg, intravenous)
Study: 11422014
Drug: p-Aminohippuric acid
Normalized name: p-aminohippuric acid
DrugBank: Aminohippuric acid (DB00345)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: p-Aminohippuric acid (PAH; 440 mg, intravenous)
Study: 11422014
Drug: Rac-pindolol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rac-pindolol (15 mg, oral)
Study: 11422014
Drug: S-pindolol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-pindolol (15 mg, oral)
Study: 11422014
Drug: Fluconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (100 mg, oral)